Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL29619648 | 0.96 | KDM4E (0.44) | KDM4EHPGDALDH1A1HSD17B10IRAK4 | |
| Potassium Ion SCHEMBL1002905 | 0.96 | KDM4E (0.44) | KDM4EHPGDALDH1A1HSD17B10IRAK4 | |
| SCHEMBL2514158 | 0.84 | CTSD (0.56) | KDM4EHPGDALDH1A1HSD17B10CTSD | |
| SCHEMBL7672827 | 0.82 | IRAK4 (0.59) | KDM4EHPGDALDH1A1HSD17B10IRAK4 | |
| Potassium Ion SCHEMBL29026645 | 0.80 | CTSD (0.56) | HPGDALDH1A1HSD17B10CTSDHTT | |
| Lithium Ion SCHEMBL7961800 | 0.80 | CTSD (0.56) | HPGDALDH1A1HSD17B10CTSDHTT | |
| Zinc Ion SCHEMBL10404876 | 0.80 | CTSD (0.56) | HPGDALDH1A1HSD17B10CTSDHTT | |
| SCHEMBL1333594 | 0.80 | CTSD (0.56) | HPGDALDH1A1HSD17B10CTSDHTT | |
| SCHEMBL31664325 | 0.80 | KDM4E (0.61) | KDM4EHPGDALDH1A1HSD17B10HTT | |
| SCHEMBL5459 | 0.80 | KDM4E (0.61) | KDM4EHPGDALDH1A1HSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025014889-A2 | SEMAGLUTIDE FORMULATIONS | PROCOMPOUNDING, LLC (US) | 2025-01-16 | — | — | WO | claimed |
| CN-116270598-A | Pharmaceutical composition comprising tedenob and use of tedenob in the treatment of breast cancer | 云南大益微生物技术有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3154533-A1 | METHODS OF ANESTHETIZING NERVE TISSUE IN THE TRIGEMINAL NERVE PATHWAY AND MEDICAL USES THEREOF | Loewi LLC (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015195708-A1 | METHODS OF ANESTHETIZING NERVE TISSUE IN THE TRIGEMINAL NERVE PATHWAY AND MEDICAL USES THEREOF | Loewi LLC (US) | 2015-12-23 | — | — | WO | claimed |
| EP-0035770-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A GLYCOSIDIC ANTIBIOTIC AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1986-12-30 | — | — | EP | claimed |
| CN-122031336-A | Whitening and freckle-removing composition based on multi-channel synergy and application thereof | 广州诺彦生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250248424-A1 | DEUTERATED CAFFEINE AND USES THEREOF | Lennham Pharmaceuticals, Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12378194-B2 | N, n-dimethyltryptamine salts and crystalline salt forms | ATAI THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025014889-A2 | SEMAGLUTIDE FORMULATIONS | PROCOMPOUNDING, LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-12194046-B2 | D9-caffeine compositions and uses thereof | Lennham Pharmaceuticals, Inc. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20070116761-A1 | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | ABRAXIS BIOSCIENCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070092563-A1 | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | ABRAXIS BIOSCIENCE, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093547-A1 | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | ABRAXIS BIOSCIENCE, LLC | 2007-04-26 | — | — | US | disclosed |
| US-20070087022-A1 | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | ABRAXIS BIOSCIENCE, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1023050-A4 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | AMERICAN BIOSCIENCE INC (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1023050-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | Vivorx Pharmaceuticals, Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999000113-A9 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS INC (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999000113-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194046-B2 | D9-caffeine compositions and uses thereof | SCN9A, CCR9, ADCY9 | PTGS1 2699/4885PTGS2 3360/4885CA2 504/4885 |
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, HTR1D, HTR1A | PTGS1 2030/4885PTGS2 2179/4885CA2 351/4885 |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, SLC6A2, SLC18A2 | PTGS1 3393/4885PTGS2 2740/4885CA2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.